Clinical characteristics
| Patient ID . | Age, y/sex . | Rai stage . | Previous therapy . | WBC count, 1000/μL . | CD5+/CD19+, percentage . |
|---|---|---|---|---|---|
| CLL030 | 62/male | 1 | Id-KLH vaccine, IVIG | 28.3 | 91.4 |
| CLL037 | 72/female | 1 | No prior therapy | 137.3 | 84.5 |
| CLL078 | 75/female | 0 | No prior therapy | 118.4 | 97.4 |
| CLL107 | 83/male | 3 | Fludarabine, Cytoxan, IVIG | 52.2 | 97.0 |
| CLL113 | 63/female | 3 | No prior therapy | 214.5 | 95.8 |
| Patient ID . | Age, y/sex . | Rai stage . | Previous therapy . | WBC count, 1000/μL . | CD5+/CD19+, percentage . |
|---|---|---|---|---|---|
| CLL030 | 62/male | 1 | Id-KLH vaccine, IVIG | 28.3 | 91.4 |
| CLL037 | 72/female | 1 | No prior therapy | 137.3 | 84.5 |
| CLL078 | 75/female | 0 | No prior therapy | 118.4 | 97.4 |
| CLL107 | 83/male | 3 | Fludarabine, Cytoxan, IVIG | 52.2 | 97.0 |
| CLL113 | 63/female | 3 | No prior therapy | 214.5 | 95.8 |
All are Zap70+ and CD38−.
WBC indicates white blood cells; Id-KLH, idiotype conjugated to keyhole limpet hemocyanin; and IVIG, intravenous immunoglobulin G.